- Home
- TLSI vs NKTX Comparison
TLSI vs NKTX Comparison
Compare TLSI & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- NKTX
- Stock Information
- Founded
- TLSI 2010
- NKTX 2015
- Country
- TLSI United States
- NKTX United States
- Employees
- TLSI N/A
- NKTX N/A
- Industry
- TLSI Medical Specialities
- NKTX Biotechnology: Pharmaceutical Preparations
- Sector
- TLSI Health Care
- NKTX Health Care
- Exchange
- TLSI Nasdaq
- NKTX Nasdaq
- Market Cap
- TLSI 160.4M
- NKTX 131.3M
- IPO Year
- TLSI N/A
- NKTX 2020
- Fundamental
- Price
- TLSI $5.19
- NKTX $1.95
- Analyst Decision
- TLSI Strong Buy
- NKTX Strong Buy
- Analyst Count
- TLSI 6
- NKTX 6
- Target Price
- TLSI $11.75
- NKTX $15.00
- AVG Volume (30 Days)
- TLSI 34.3K
- NKTX 675.7K
- Earning Date
- TLSI 05-14-2025
- NKTX 05-20-2025
- Dividend Yield
- TLSI N/A
- NKTX N/A
- EPS Growth
- TLSI N/A
- NKTX N/A
- EPS
- TLSI N/A
- NKTX N/A
- Revenue
- TLSI $29,431,000.00
- NKTX N/A
- Revenue This Year
- TLSI $56.00
- NKTX N/A
- Revenue Next Year
- TLSI $52.17
- NKTX N/A
- P/E Ratio
- TLSI N/A
- NKTX N/A
- Revenue Growth
- TLSI 58.99
- NKTX N/A
- 52 Week Low
- TLSI $3.50
- NKTX $1.31
- 52 Week High
- TLSI $10.24
- NKTX $8.23
- Technical
- Relative Strength Index (RSI)
- TLSI 40.35
- NKTX 51.98
- Support Level
- TLSI $4.66
- NKTX $1.81
- Resistance Level
- TLSI $5.35
- NKTX $2.16
- Average True Range (ATR)
- TLSI 0.37
- NKTX 0.16
- MACD
- TLSI -0.05
- NKTX -0.02
- Stochastic Oscillator
- TLSI 43.44
- NKTX 34.00
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.